July 24, 2018 : DCMS #407

DISASTERS AVERTED — Near Miss Case Studies

Accidents Will Happen But Damage Can Be Minimized

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Aaron Vinik on the Pathogenesis of Diabetes

HOMERUN SLIDES — Great Clinical Presentation Highlights

Pathophysiology of Type 1 Diabetes Part 1

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #135: Pathogenesis of Type 2 Diabetes Mellitus Part 6

MOST POPULAR ARTICLES OF THE MONTH

#1 How Much Monitoring is Too Much?
#2 Amazing Outcomes with Combination Therapy of GLP-1 Receptor Agonist and SGLT2 Inhibitors
#3 Relationship Between HbA1c and Stroke Risk

Way back in 2002 we had an article on in our newsletter on the newly discovered INGAP peptide (https://www.diabetesincontrol.com/issue-111-item-19-ingap-peptide-an-initiator-of-beta-cell-growth/ ) This peptide was thought to be able to regenerate beta cells, and early on it looked like a possible cure. Over the past 16 years we have had multiple features on the rise and fall of INGAP therapy. A couple of months ago one of our Pharm. D interns came to Steve and me to find out what ever happened to this research. Our Publisher, Steve Freed, caught up with Dr. Aaron Vinik at the AACE meeting in Boston to find out the latest.

Dave Joffe

Editor-in-chief

 Over the years, I have had many patients come into the pharmacy requesting a replacement bottle of insulin because they’ve accidentally dropped a bottle. Recently, a patient shared one such experience….

AARON I. VINIK, MD, PhD, FCP, MACP, FACE is a global leader in basic and clinical neuropathy. He, in essence, has defined the heterogeneity of neuropathy, established a need for a modular approach depending on the particular nerve fiber damaged, and pioneered immunotherapy for autoimmune neuropathies.  He was awarded a lifetime achievement award by EASD Neurodiab in 2011 for his contributions to the understanding of neuropathies. In 2016, he received the American College of Endocrinology (AACE) Distinction in Endocrinology Award in recognition of advancing the understanding of endocrinology through research and education.

In this week’s Homerun Slides, understanding the disorder of type 1 diabetes and a summary of glycemic recommendations.

In utero fetal malnutrition: Low birth weight is associated with the development of IGT and T2DM in a number of populations. Developmental studies in animals and humans have demonstrated that poor nutrition and impaired fetal growth (small babies at birth) are associated with impaired insulin secretion and/or reduced beta-cell mass. Fetal malnutrition can also lead to the development of insulin resistance later in life.

What I love about going to conferences is the realization that what I’m doing in my practice is in line with what others I respect are doing. That is meaningful, and I always learn a new pearl. If that’s all I gain from these conferences, it’s okay, but it’s usually more than that.

I have just returned from the 2018 ADA Conference, where there was so much about new technology, particularly continuous glucose monitoring.

The different mechanisms of action of these two drugs make them an excellent combination in the treatment of patients with type 2 diabetes mellitus (T2DM).

New meta-analysis striving to expand on the notion that glycemic control and stroke risk are closely associated.